Core Viewpoint - Ensysce Biosciences, Inc. has received a Notice of Allowance from the Brazilian Patent Office for a patent covering additional opioid families, enhancing its intellectual property and expanding global protection for its innovative pain treatment technologies [1] Group 1: Patent and Technology - The newly allowed patent includes both composition of matter and method of use claims, which strengthens the company's intellectual property estate [1] - The patent covers the company's proprietary TAAP™ (Trypsin Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance) technologies, aimed at advancing safer pain treatment [1] Group 2: Market Implications - The expansion of patent protection is expected to bolster the company's position in the market for Next Generation analgesics, potentially leading to increased competitiveness and market share [1]